Skip to search formSkip to main contentSkip to account menu

darexaban

Known as: N-(2-hydroxy-6-(4-methoxybenzamido)phenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

AzepinesBenzamidesFactor Xa inhibitors

Narrower (1)

YM 150

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Advances in oral anticoagulation therapy - What's in the pipeline?
Review
2015
Review
2015
Direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease
Atherosclerotic disease is the leading cause of morbidity and mortality worldwide. Despite advances in the medical treatment to… 
2015
2015
A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral…
Darexaban (YM150) is a novel oral anticoagulant that directly inhibits factor Xa. 
2014
2014
Darexaban for the Prevention of Venous Thromboembolism in Asian Patients Undergoing Orthopedic Surgery
Objective: To evaluate the efficacy and safety of darexaban (YM150) in Asian patients undergoing total hip or total knee… 
Review
2014
Review
2014
The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial… 
2014
2014
Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates.
Review
2013
Review
2013
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
Background Oral anticoagulation in addition to antiplatelet treatment after an acute coronary syndrome might reduce ischaemic… 
Review
2012
Review
2012
Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation.
Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… 
Review
2012
Review
2012
Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban
Introduction: Inhibition of the pathways of anticoagulation is widely used for the prevention and treatment of arterial and… 
2011
2011
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)